Covid-19 roundup: AstraZeneca builds $261M deal with US CDMO player for bulk Covid-19 vaccine supply; Corporate insiders reeling in over $1B+
Less than 2 months after BARDA spearheaded US efforts to ensure a large supply of vaccine to fight Covid-19 with a $628 million alliance with Emergent BioSolutions, AstraZeneca has stepped up with a new, $174 million add-on contract for its CDMO operation to produce their Oxford vaccine at scale in Emergent’s Baltimore facility.
AstraZeneca promised it could deliver 2 billion doses of their vaccine to the world next year, making it one of the leading players in the drive to inoculate the world against Covid-19. This new contract development and commercialization pact builds on their initial $87 million contract regarding AZD1222, which they signed in June.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.